Long Term Results Confirm The Survival Benefit Of Taxotere®-based Treatment In Patients With Metastatic Hormone Refractory Prostate Cancer
Mon, 26 Feb 2007 05:00 PM EST
... Sanofi-aventis announced, at the ASCO Prostate Cancer Symposium, long term survival results of the large TAX 327 Phase III clinical trial. [click link for full article] ...

Not Signed In -


